The University of Chicago Header Logo

Connection

Everett Vokes to Sirolimus

Back to Details
This is a "connection" page, showing publications Everett Vokes has written about Sirolimus.
Everett Vokes
Connection Strength
0.992
Sirolimus
  1. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer. 2020 07 15; 126(14):3237-3243.
    View in: PubMed
    Score: 0.587
  2. Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer. Oncol Rep. 2012 May; 27(5):1625-9.
    View in: PubMed
    Score: 0.331
  3. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 01; 28(31):4740-6.
    View in: PubMed
    Score: 0.075
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.